Published in Arch Dermatol on April 01, 2006
Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol (2010) 1.48
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol (2011) 0.94
Skin self-examination education for early detection of melanoma: a randomized controlled trial of Internet, workbook, and in-person interventions. J Med Internet Res (2014) 0.87
Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients. Dermatol Res Pract (2009) 0.85
Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol (2010) 0.84
The experience of melanoma follow-up care: an online survey of patients in australia. J Skin Cancer (2014) 0.78
Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population. Br J Dermatol (2013) 0.77
Diagnosis of skin lesions by trainee surgeons: experience improves accuracy. Ann R Coll Surg Engl (2009) 0.75
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Setting priorities in global child health research investments: assessment of principles and practice. Croat Med J (2007) 3.24
Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol (2002) 3.13
Setting priorities in global child health research investments: universal challenges and conceptual framework. Croat Med J (2008) 2.93
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Alcohol use in motion pictures and its relation with early-onset teen drinking. J Stud Alcohol (2006) 2.73
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol (2009) 2.32
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology (2003) 2.00
Exposure to movie smoking among US adolescents aged 10 to 14 years: a population estimate. Pediatrics (2007) 1.95
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS (2010) 1.76
Use of tanning devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst (2002) 1.70
Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol (2013) 1.65
Management of hypoplastic left heart syndrome in the 1990s. Am J Cardiol (2002) 1.61
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol (2002) 1.60
Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol (2002) 1.58
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (2009) 1.51
Ownership of alcohol-branded merchandise and initiation of teen drinking. Am J Prev Med (2006) 1.50
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Gene-drug interaction at the glucocorticoid receptor increases risk of squamous cell skin cancer. J Invest Dermatol (2007) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol (2014) 1.45
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology (2013) 1.44
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (2011) 1.41
Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer (2005) 1.40
Nutrition and exercise environment available to outpatients, visitors, and staff in Children's hospitals in Canada and the United States. Arch Pediatr Adolesc Med (2006) 1.34
Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution. Cytometry A (2008) 1.33
Microsatellite instability at tetranucleotide repeats in skin and bladder cancer. Oncogene (2002) 1.33
Racial variation in treatment preferences and willingness to randomize in the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976) (2006) 1.32
Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol (2005) 1.28
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Early life factors in relation to breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2002) 1.20
Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ (2010) 1.18
Expressive disclosure and health outcomes in a prostate cancer population. Int J Psychiatry Med (2002) 1.17
Measures of cumulative exposure from a standardized sun exposure history questionnaire: a comparison with histologic assessment of solar skin damage. Am J Epidemiol (2007) 1.11
Exposure to sunlamps, tanning beds, and melanoma risk. Cancer Causes Control (2008) 1.11
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res (2006) 1.10
Folic acid and prevention of colorectal adenomas: a combined analysis of randomized clinical trials. Int J Cancer (2011) 1.09
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol (2011) 1.07
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 1.05
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer (2013) 1.05
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05
VISTA is an immune checkpoint molecule for human T cells. Cancer Res (2014) 1.03
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother (2011) 1.02
Correlation of serum hormone concentrations in maternal and umbilical cord samples. Cancer Epidemiol Biomarkers Prev (2003) 1.02
Tea consumption and basal cell and squamous cell skin cancer: results of a case-control study. J Am Acad Dermatol (2007) 1.02
Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol (2011) 1.00
A population-based case-control study of urinary arsenic species and squamous cell carcinoma in New Hampshire, USA. Environ Health Perspect (2013) 0.99
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol (2008) 0.99
Clinical electron paramagnetic resonance (EPR) oximetry using India ink. Adv Exp Med Biol (2010) 0.98
Rapid measurement of total acid content (TAC) in vinegar using near infrared spectroscopy based on efficient variables selection algorithm and nonlinear regression tools. Food Chem (2012) 0.97
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS (2003) 0.97
Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol (2007) 0.96
Movie character smoking and adolescent smoking: who matters more, good guys or bad guys? Pediatrics (2009) 0.94
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis (2007) 0.93
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol (2006) 0.92
Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol (2008) 0.92
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 0.92
Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med (2009) 0.92
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology (2010) 0.91
A role for ultraviolet radiation immunosuppression in non-melanoma skin cancer as evidenced by gene-environment interactions. Carcinogenesis (2008) 0.91
Communication of bed allocation decisions in a critical care unit and accountability for reasonableness. BMC Health Serv Res (2005) 0.91
Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. J Invest Dermatol (2006) 0.90
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study. Int J Cancer (2013) 0.89
Pulmonary adenocarcinoma with metastasis to skeletal muscle in a cat. Can Vet J (2006) 0.89
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res (2007) 0.88
Self-recognition and tumor response to immunotherapy. J Clin Oncol (2005) 0.87
Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature. J Clin Oncol (2011) 0.87
Been there, not done that--melanoma in the age of molecular therapy. N Engl J Med (2011) 0.87
Centralized drug review processes: are they fair? Soc Sci Med (2006) 0.87
Multiparameter precursor analysis of T-cell responses to antigen. J Immunol Methods (2003) 0.87
Using evaluation theory in priority setting and resource allocation. J Health Organ Manag (2012) 0.87
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol (2003) 0.86